NKY(SZ:300109)2022-11-11 03:26Financial Performance - In the first half of 2022, the company achieved operating revenue of 67,842.79 million yuan, a year-on-year increase of 26.48% [2] - Operating profit reached 18,392.35 million yuan, up 66.91% compared to the same period last year [2] - Net profit attributable to the parent company was 14,610.75 million yuan, reflecting a growth of 75.05% year-on-year [2] - The primary reason for this growth is attributed to the increase in the chemical segment's business compared to the previous year [2] Product Overview - The company's product, Euriz, is a linear molecular structure, water-soluble electrolyte polymer with excellent chemical stability and non-toxicity, widely used in various fields [3] - As of June 30, 2022, Euriz sales increased by over 300 tons compared to the same period last year, with an expected total sales of over 1,000 tons in 2022, indicating significant growth potential [3] Chemical Business Insights - The PVP series products are recognized as one of the three major new pharmaceutical excipients, with applications extending beyond traditional pharmaceuticals to various industrial sectors [3][4] - The company has established a production capacity of 10,000 tons of PVP, with plans to increase annual production to 13,000 tons through technological upgrades and research investments [4] - The company has a market share of approximately 50% in the domestic PVP segment, serving over 1,000 clients across 30 different downstream sectors [4] Market Position and Competition - The company has been deeply engaged in the PVP niche market for nearly 20 years and is one of the earliest domestic manufacturers to obtain cGMP certification [4] - There are no recent expansion plans from foreign competitors, while some domestic competitors have announced expansion plans [4] - The company is set to launch a PVP expansion project in the Qiaozao Zhongzhan area, expected to be operational by Q2 2023, which will increase its production capacity to 30,000 tons [4]